[HTML][HTML] Epigenetics in pancreatic ductal adenocarcinoma: impact on biology and utilization in diagnostics and treatment
Simple Summary Epigenetic alterations contribute to the distinct biology of pancreatic ductal
adenocarcinoma (PDAC) and thus allow a better understanding of molecular mechanisms …
adenocarcinoma (PDAC) and thus allow a better understanding of molecular mechanisms …
[HTML][HTML] Epigenetic control of pancreatic cancer metastasis
L Krauß, C Schneider, E Hessmann, D Saur… - Cancer and Metastasis …, 2023 - Springer
Surgical resection, when combined with chemotherapy, has been shown to significantly
improve the survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) …
improve the survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) …
Design and conduct considerations for studies in patients with hepatic impairment
P Ravenstijn, M Chetty, P Manchandani… - Clinical and …, 2023 - Wiley Online Library
Despite the liver being the primary site for clearance of xenobiotics utilizing a myriad of
mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary …
mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary …
[HTML][HTML] Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
PJ Voon, EX Chen, HX Chen, AC Lockhart… - Journal of Experimental …, 2022 - Springer
Background Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended
phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D …
phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D …
Impact of organ impairment on the pharmacokinetics of therapeutic peptides and proteins
EP Fletcher, M Sahre, YY Hon, A Balakrishnan… - The AAPS Journal, 2023 - Springer
The kidneys and liver are major organs involved in eliminating small-molecule drugs from
the body. Characterization of the effects of renal impairment (RI) and hepatic impairment (HI) …
the body. Characterization of the effects of renal impairment (RI) and hepatic impairment (HI) …
Epigenetic therapeutic strategies in pancreatic cancer.
A Orlacchio, S Muzyka, TA Gonda - International Review of Cell and …, 2024 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies,
characterized by its aggressiveness and metastatic potential, with a 5-year survival rate of …
characterized by its aggressiveness and metastatic potential, with a 5-year survival rate of …